Manjunath M, Prajapat Deepak, Sharma Rahul Kumar, Talwar Deepak
Metro Centre for Respiratory Diseases, Metro Multispecialty Hospital, Noida, Uttar Pradesh, India.
Lung India. 2018 Jan-Feb;35(1):70-72. doi: 10.4103/lungindia.lungindia_535_16.
Pulmonary mucormycosis is a life-threatening opportunistic fungal infection. It is considered as a disease of immunocompromised state and is rarely seen in immunocompetent patients. We here report a case of refractory bronchovascular pleuropulmonary mucormycosis, who despite early detection, optimal management with liposomal amphotericin B, and posaconazole therapy followed by surgery, progressed further and led to a fatal outcome. Dual antifungal therapy combined with surgery is the only definitive treatment option available in the literature. Many new therapeutic options for mucormycosis treatment have become available but none have shown promising results, and larger studies are required to assess their efficacy.
肺毛霉病是一种危及生命的机会性真菌感染。它被认为是免疫功能低下状态下的疾病，在免疫功能正常的患者中很少见。我们在此报告一例难治性支气管血管胸膜肺毛霉病病例，该患者尽管早期发现、采用脂质体两性霉素B进行了最佳治疗、泊沙康唑治疗后又接受了手术，但病情仍进一步进展并导致了致命结局。双重抗真菌治疗联合手术是文献中唯一可用的确定性治疗选择。目前已有许多治疗毛霉病的新治疗选择，但均未显示出有希望的结果，需要进行更大规模的研究来评估它们的疗效。
